TScan Therapeutics, Inc. (TCRX)
NASDAQ: TCRX · Real-Time Price · USD
1.890
+0.020 (1.07%)
Sep 4, 2025, 4:00 PM - Market closed
TScan Therapeutics Stock Forecast
Stock Price Forecast
The 5 analysts that cover TScan Therapeutics stock have a consensus rating of "Strong Buy" and an average price target of $9.40, which forecasts a 397.35% increase in the stock price over the next year. The lowest target is $3.00 and the highest is $15.
Price Target: $9.40 (+397.35%)
Analyst Consensus: Strong Buy
* Price targets were last updated on May 7, 2025.
Analyst Ratings
The average analyst rating for TScan Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 4 | 4 | 4 | 3 |
| Buy | 3 | 3 | 3 | 3 | 3 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 6 | 7 | 7 | 7 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $15 → $10 | Strong Buy | Maintains | $15 → $10 | +429.10% | May 7, 2025 |
| Needham | Needham | Strong Buy Reiterates $9 | Strong Buy | Reiterates | $9 | +376.19% | Apr 8, 2025 |
| Morgan Stanley | Morgan Stanley | Buy Initiates $10 | Buy | Initiates | $10 | +429.10% | Mar 14, 2025 |
| Barclays | Barclays | Buy Maintains $14 → $3 | Buy | Maintains | $14 → $3 | +58.73% | Mar 7, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $15 | Strong Buy | Reiterates | $15 | +693.65% | Mar 6, 2025 |
Financial Forecast
Revenue This Year
10.00M
from 2.82M
Increased by 255.18%
Revenue Next Year
8.59M
from 10.00M
Decreased by -14.14%
EPS This Year
-1.16
from -2.25
EPS Next Year
-1.22
from -1.16
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 15.8M | 25.4M | |||
| Avg | 10.0M | 8.6M | |||
| Low | 6.1M | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 459.3% | 153.9% | |||
| Avg | 255.2% | -14.1% | |||
| Low | 115.8% | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -1.10 | -0.96 | |||
| Avg | -1.16 | -1.22 | |||
| Low | -1.16 | -1.70 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.